Objective:
To evaluate the efficacy and safety of aflibercept 8 mg compared to aflibercept 2 mg in treatment-naïve patients with macular edema secondary to retinal vein occlusion (RVO).
Key Findings:
- Aflibercept 8 mg achieved noninferior vision gains compared to 2 mg with fewer injections.
- Patients in the 8 mg group required an average of 6.1 injections at week 36, compared to 8.8 in the 2 mg group.
- Approximately 70% of patients in the 8 mg group had a last assigned dosing interval of every 12 weeks.
- Safety outcomes showed no new concerns, and aflibercept 8 mg was well tolerated.
Interpretation:
Aflibercept 8 mg may reduce treatment burden without compromising efficacy in patients with RVO, demonstrating consistent outcomes across different RVO subtypes.
Limitations:
- The trial is ongoing, with final data readout expected after week 64.
- Long-term visual durability and optimal sequencing in clinical practice are yet to be fully analyzed.
Conclusion:
Aflibercept 8 mg offers a promising alternative for managing RVO, potentially allowing for less frequent dosing while maintaining visual and anatomic improvements.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.